Joanna Ling Zhi Jie

Joanna Ling Zhi Jie

Auto-generated profile, based on publicly available information

Joanna Ling Zhi Jie

Observational and Pragmatic Research Institute, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
DPDavid B Price
David B Price
FTFrank Trudo
Frank Trudo
JVJaco Voorham
Jaco Voorham
XXXiao Xu
Xiao Xu
MKMarjan Kerkhof
Marjan Kerkhof
TTTrung N Tran
Trung N Tran
Purpose: Prior work suggests a threshold of four courses/year of systemic corticosteroid (SCS) therapy is associated with adverse consequences. The objective of this study was to investigate the onset of adverse outcomes beginning at SCS initiation in a broad asthma population. Patients and methods: This historical matched cohort study utilized anonymized, longitudinal medical record data (1984–2017) of patients (≥18 years) with active asthma. Matched patients with first SCS prescription (SCS arm) and no SCS exposure (non-SCS arm) were followed until first outcome event. Associations between time-varying exposure measures and onset of 17 SCS-associated adverse outcomes were estimated using Cox proportional hazard regression, adjusting for confounders, in separate models. Results: We matched 24,117 pairs of patients with median record availability before SCS initiation of 9.9 and 8.7 years and median follow-up 7.4 and 6.4 years in SCS and non-SCS arms, respectively. Compared with patients in the non-SCS arm, patients prescribed SCS had significantly increased risk of osteoporosis/osteoporotic fracture (adjusted hazard ratio 3.11; 95% CI 1.87–5.19), pneumonia (2.68; 2.30–3.11), cardio-/cerebrovascular diseases (1.53; 1.36–1.72), cataract (1.50; 1.31–1.73), sleep apnea (1.40; 1.04–1.86), renal impairment (1.36; 1.26–1.47), depression/anxiety (1.31; 1.21–1.41), type 2 diabetes (1.26; 1.15–1.37), and weight gain (1.14; 1.10–1.18). A dose-response relationship for cumulative SCS exposure with most adverse outcomes began at cumulative exposures of 1.0–<2.5 g and for some outcomes at cumulative exposures of only 0.5–0–<0.5 g reference), equivalent to four lifetime SCS courses. Conclusion: Our findings suggest urgent need for reappraisal of when patients need specialist care and consideration of nonsteroid therapy.

10 July 2018 in Allergy
Verified
Journal Article
Open access
PDF file
JVJaco Voorham
Jaco Voorham
XXXiao Xu
Xiao Xu
DPDavid B. Price
David B. Price
SGSarowar Golam
Sarowar Golam
JDJill Davis
Jill Davis
TTTrung N. Tran
Trung N. Tran
Background: Although systemic corticosteroid (SCS) treatment, irrespective of duration or dosage, is associated with adverse outcomes for patients with asthma, the longitudinal effects of this treatment on adverse outcomes, healthcare resource utilization (HCRU), and healthcare costs are unknown.Methods: We identified patients initiating intermittent or long‐term SCS who were diagnosed with active asthma from UK general practice with linked secondary care data. Control (non‐SCS) patients were matched by sex and index date with those initiating SCS. Minimum baseline period was 1 year prior to index date; minimum follow‐up duration was 2 years post–index date. Cumulative incidence of SCS‐associated adverse outcomes and associated HCRU and costs were compared between SCS and non‐SCS patient groups and among average SCS daily exposure categories. Associations between exposure and annualized HCRU and costs were assessed, adjusted for confounders.Results: Analyses included 9413 matched pairs. Median (interquartile range) follow up was as follows: SCS group: 7.1 (4.1‐11.8) years; control group: 6.4 (3.8‐10.0) years. Greater SCS dosages were correlated with greater cumulative incidence. For example, patients with type 2 diabetes receiving an average daily dosage of ≥7.5 mg had a 15‐year cumulative incidence (37.5%) that was 1.5‐5 times greater than those receiving lower dosages. HCRU and costs increased annually for SCS patients but not for non‐SCS patients. Increases in all‐cause adverse outcome (excluding asthma)–associated HCRU and costs were dose‐dependent.Conclusions: Over the long term, adverse outcomes associated with SCS initiation were relatively frequent and costly, with a positive dosage–response relationship with SCS exposure.

5 July 2016 in Heart
Verified
Journal Article
Open access
PDF file
BLBrian Lipworth
Brian Lipworth
DSDerek Skinner
Derek Skinner
GDGraham Devereux
Graham Devereux
VTVictoria Thomas
Victoria Thomas
JJJoanna Ling Zhi Jie
Joanna Ling Zhi Jie
DPDavid B Price
David B Price
Objective Although β-blockers are an established therapy in heart failure (HF) guidelines, including for patients with chronic obstructive pulmonary disease (COPD), there remain concerns regarding bronchoconstriction even with cardioselective β-blockers. We wished to assess the real-life use of β-blockers for patients with HF and comorbid COPD. Methods We evaluated data from the Optimum Patient Care Research Database over a period of 1 year for co-prescribing of β-blockers with either an ACE inhibitor (ACEI) or angiotensin-2 receptor blocker (ARB) in patients with HF alone versus HF+COPD. Association with inhaler therapy was also evaluated. Results We identified 89 861 patients with COPD, 24 237 with HF and 10 853 with both conditions. In patients with HF+COPD, the mean age was 79 years; 60% were male, and 27% had prior myocardial infarction. Of patients with HF+COPD, 22% were taking a β-blocker in conjunction with either ACEI/ARB (n=2416) compared with 41% of patients with HF only (n=10 002) (adjusted OR 0.54, 95% CI 0.51 to 0.58, p<0.001). Among HF+COPD patients taking inhaled corticosteroid (ICS) with long-acting β-agonist (LABA) and long-acting muscarinic antagonist, 27% of patients were taking an ACEI/ARB with β-blockers (n=778) versus 46% taking an ACEI/ARB without β-blockers (n=1316). Corresponding figures for those patients taking ICS/LABA were 20% (n=583) versus 48% (n=1367), respectively. Conclusions These data indicate a substantial unmet need for patients with COPD who should be prescribed β-blockers more often for concomitant HF.

14 March 2020 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
MFMariana Alves Fonseca
Mariana Alves Fonseca
JLJoanna Zhi Jie Ling
Joanna Zhi Jie Ling
OAOmar Al‐Siyabi
Omar Al‐Siyabi
VCVanessa Co‐Tanko
Vanessa Co‐Tanko
ECEdwin Chan
Edwin Chan
SLSeng Gee Lim
Seng Gee Lim

14 June 2019 in JMIR Mental Health
Verified
Journal Article
Open access
XLXiangting Bernice Lin
Xiangting Bernice Lin
TLTih-Shih Lee
Tih-Shih Lee
YCYin Bun Cheung
Yin Bun Cheung
JLJoanna Ling
Joanna Ling
SPShi Hui Poon
Shi Hui Poon
CGCuntai Guan
Cuntai Guan
Background: Exposure therapy is highly effective for social anxiety disorder. However, there is room for improvement. Objective: This is a first attempt to examine the feasibility of an arousal feedback–based exposure therapy to alleviate social anxiety symptoms in an analogue adult sample. Methods: A randomized, pilot, proof-of-concept trial was conducted to evaluate the acceptability, safety, and preliminary efficacy of our treatment program. Sessions were administered once a week for 4 weeks (1 hour each) to an analogue sample of 50 young adults who reported at least minimal social anxiety symptoms. Participants in both intervention and waitlist control groups completed assessments for social anxiety symptoms at the baseline, week 5, and week 10. Results: Most participants found the intervention acceptable (82.0%, 95% CI 69.0%-91.0%). Seven (14.9%, 95% CI 7.0%-28.0%) participants reported at least one mild adverse event over the course of study. No moderate or serious adverse events were reported. Participants in the intervention group demonstrated greater improvements on all outcome measures of public speaking anxiety from baseline to week 5 as compared to the waitlist control group (Cohen d=0.61-1.39). Effect size of the difference in mean change on the overall Liebowitz Social Anxiety Scale was small (Cohen d=0.13). Conclusions: Our results indicated that it is worthwhile to proceed to a larger trial for our treatment program. This new medium of administration for exposure therapy may be feasible for treating a subset of social anxiety symptoms. Additional studies are warranted to explore its therapeutic mechanisms. Trial Registration: ClinicalTrials.gov NCT02493010; https://clinicaltrials.gov/ct2/show/NCT02493010

17 February 2018 in Family Practice
Verified
Journal Article
Closed access
YLYee Wei Lim
Yee Wei Lim
JLJoanna Ling
Joanna Ling
ZLZoe Lim
Zoe Lim
ACAudrey Chia
Audrey Chia
Background. Singapore's health care system is strained by the health care needs of a rapidly aging population. The unprecedented collaboration between a public hospital and a private family practice to set up the Family Medicine Clinic (FMC) to co-manage patients with chronic disease is an example of efforts to shift care to the community. Objective. To explore patients' initial experience of shared chronic disease care in a private family practice setting. Methods. In this exploratory case study, we surveyed 330 patients with stable chronic diseases and interviewed 10 complex care patients and their caregivers. Results. Most patients were willing to transfer their care from the hospital to a FMC and satisfied with the care received. Patients reported enhanced access at FMC and appreciated the improvement in care continuity and care coordination across settings. Patients with complex care needs felt engaged with their case manager even though they did not understand case management. Despite the favourable assessment of FMC, patients sought care from other health care providers and a third of patients would leave if the subsidy for their care at FMC was removed. Families and caregivers felt that their needs could be better addressed and that FMC could play a role. Conclusions. To ensure that patients' initial positive experience translates to a long-term relationship with FMC, providers should move beyond providing improved access to care. It is necessary to help patients understand the comparative advantage of community-based care and its contribution to long-term health outcomes. Providers should also elicit patients' desires and expectations when designing future models of care. At a policy level, higher cost of private primary care should be addressed.